Sangamo is pioneering the future of genomic medicine
Sangamo Therapeutics is a genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical programs. Our platforms have yielded multiple clinical stage programs that could provide value in the near-to-mid-term. We have a robust preclinical pipeline with programs in emerging areas that could provide value in the mid-to-long term. Our goal is to develop a wholly owned genomic medicine portfolio, which we fund via our collaborations with blue-chip biopharmaceutical partners, which have already brought in $815M in upfronts and milestones with billions in potential milestone payments. We believe that manufacturing is a strategic advantage and gives us greater control over timelines, quality and supply. Our ability to fund our projects enables us to execute and deliver on our mission.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
January 6, 2022
The Companies are collaborating on an orderly transition through first half of 2022 while Sangamo explores options to advance the program, including seeking a new partner Phase 1/2 PRECIZN-1 study of investigational SAR445136 expected to be completed as planned; final patients in study expected to
January 4, 2022
BRISBANE, Calif. --(BUSINESS WIRE)--Jan. 4, 2022-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will provide a corporate presentation at the H.C. Wainwright BIOCONNECT Virtual Conference on Monday, January 10 th at 7:00 a.m. Eastern Time .
December 12, 2021
NEW YORK & BRISBANE, Calif. --(BUSINESS WIRE)--Dec. 12, 2021-- Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec, an investigational gene therapy
December 12, 2021
- No adverse events related to investigational SAR445136 were reported - All four treated patients experienced increases in total hemoglobin, fetal hemoglobin and percent F cells; none required blood transfusions post engraftment BRISBANE, Calif. --(BUSINESS WIRE)--Dec.